- Home
- VRDN vs EWTX Comparison
VRDN vs EWTX Comparison
Compare VRDN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- EWTX
- Stock Information
- Founded
- VRDN 2006
- EWTX 2017
- Country
- VRDN United States
- EWTX United States
- Employees
- VRDN N/A
- EWTX N/A
- Industry
- VRDN Medical Specialities
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- EWTX Health Care
- Exchange
- VRDN Nasdaq
- EWTX Nasdaq
- Market Cap
- VRDN 1.3B
- EWTX 1.2B
- IPO Year
- VRDN N/A
- EWTX 2021
- Fundamental
- Price
- VRDN $14.34
- EWTX $13.35
- Analyst Decision
- VRDN Strong Buy
- EWTX Buy
- Analyst Count
- VRDN 11
- EWTX 8
- Target Price
- VRDN $38.50
- EWTX $39.63
- AVG Volume (30 Days)
- VRDN 750.1K
- EWTX 1.0M
- Earning Date
- VRDN 08-07-2025
- EWTX 08-07-2025
- Dividend Yield
- VRDN N/A
- EWTX N/A
- EPS Growth
- VRDN N/A
- EWTX N/A
- EPS
- VRDN N/A
- EWTX N/A
- Revenue
- VRDN $302,000.00
- EWTX N/A
- Revenue This Year
- VRDN N/A
- EWTX N/A
- Revenue Next Year
- VRDN $17,102.33
- EWTX N/A
- P/E Ratio
- VRDN N/A
- EWTX N/A
- Revenue Growth
- VRDN 4.86
- EWTX N/A
- 52 Week Low
- VRDN $9.90
- EWTX $10.60
- 52 Week High
- VRDN $27.20
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- VRDN 50.32
- EWTX 34.22
- Support Level
- VRDN $14.11
- EWTX $12.15
- Resistance Level
- VRDN $16.05
- EWTX $14.85
- Average True Range (ATR)
- VRDN 0.74
- EWTX 0.68
- MACD
- VRDN -0.13
- EWTX -0.16
- Stochastic Oscillator
- VRDN 20.18
- EWTX 23.13
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.